The 6th RNAi-Based Therapeutics Summit
As RNAi excitement continued to grow, attendees joined their peers for 3 jam-packed days dedicated to advancing your RNAi candidates into clinically relevant therapies. Curated with insight from Benitec Biopharma, Judo Bio, Novartis, and Sirnaomics, this RNAi-focused agenda will cover all things RNAi, from maximizing bioavailability with oligonucleotide conjugates, streamlining translation, overcoming off-target effects and maintaining purity during scale-up and manufacturing.
25+ Expert Speakers shared data and empowered you to:
Seized the value of novel delivery systems to maximize bioavailability and precision targeting to a wider range of tissues with insights from SanegeneBio, Avidity Biosciences and Sapreme Technologies
Unlocked the full potential of RNAi therapy by reaching previously undruggable extra-hepatic targets including the CNS, placenta, muscle and kidney, with data from Comanche Biopharma, Novo Nordisk and Judo Bio
Revolutionized
RNAi design and delivery by employing cutting edge generative AI and deep-learning based platforms to advance stable, precise extra-hepatic targeting, with expertise from Nosis Bio, Tallas Biotech and ProteinQure
Enhanced the stability, efficacy and tolerability of RNAi payloads through clever chemical modifications that suppressed off-target activity and improved durability, with research from Alnylam, Novartis, and Stony Brook University
Maximized the success of early-stage RNAi platforms and assets and attracted investment and meaningful partnerships, with insight from Sunrise Bioventures and Broadview Ventures
New & Noteworthy Sessions in 2025
"Deep Learning-based Design of Cell-targeting Ligands Enables Cell-specific, Functional siRNA Delivery in Multiple Extra-hepatic Tissues"
Chad Miller, Head of Research, Nosis Bio
“Targeted Extra-Hepatic Delivery of Custom Oligonucleotide-Peptide Conjugates for Enhanced Tumor Bioavailability, Efficacy, & Safety in a Breast Cancer Model”
Yuanyuan Jin, Co-founder & Chief Operating Officer, Bound Therapeutics
“Delivery of siRNA to the Placenta for the Treatment of Preeclampsia”
Vignesh Narayan Hariharan, Director of Biology, Comanche Biopharma & Instructor, UMass Chan Medical School
“Novel siRNA Platform for Cellular-Driven Tissue Repair & Regeneration”
David Sharp, Chief Executive Officer, MicroCures
Workshop B: “Streamlining Translation & De-risking RNAi Therapeutic Development with Optimal Selection of Preclinical Models & Appropriate Assays to Ensure Tolerable, Potent Therapies”
Mohammad Shadid, Vice President, Preclinical Development, Korro Bio
Hanhua Huang, Vice President, Biology, Avidity Biosciences